Form 4: Adial Pharmaceuticals Director Acquires Stock Options

Robertson H. Gilliland, a director of Adial Pharmaceuticals, acquired stock options exercisable for 12,000 shares of common stock.

Summary

• On March 25, 2024, Robertson H. Gilliland, a director of Adial Pharmaceuticals, acquired stock options.
• The options are exercisable for 12,000 shares of common stock at a price of $1.35 per share.
• The options vest pro rata on a monthly basis over 36 months, commencing on April 25, 2024.
• The options expire on March 24, 2034.
• Following the transaction, Gilliland directly owns options for 12,000 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, Form 4, director, acquisition, ADIL, Adial Pharmaceuticals, Gilliland, beneficial ownership